GLSI logo

Greenwich LifeSciences, Inc. Stock Price

NasdaqCM:GLSI Community·US$132.5m Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 24 Fair Values set on narratives written by author

GLSI Share Price Performance

US$9.49
-4.04 (-29.86%)
97.9% undervalued intrinsic discount
US$460.00
Fair Value
US$9.49
-4.04 (-29.86%)
97.9% undervalued intrinsic discount
US$460.00
Fair Value
Price US$9.49
White_valkyrie US$460.00

GLSI Community Narratives

White_valkyrie·
Fair Value US$460 97.9% undervalued intrinsic discount

Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.

5users have liked this narrative
1users have commented on this narrative
16users have followed this narrative

Snowflake Analysis

Adequate balance sheet with moderate growth potential.

2 Risks
1 Reward

Greenwich LifeSciences, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$18.0m

Other Expenses

-US$18.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-1.32
0%
0%
0%
View Full Analysis

About GLSI

Founded
2006
Employees
6
CEO
Snehal Patel
WebsiteView website
greenwichlifesciences.com

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Recent GLSI News & Updates

Recent updates

No updates